The Review Of
DIABETIC
STUDIES OPEN ACCESS

Neuropathic Pain: Mechanisms, Epidemiology, And Therapeutic Strategies

Abhishek Anand[1], Amit Kumar[2], Abhishek Suman[2], Mithul V Mammen*[1], Ayush Mishra[1], Ayush Mishra[1]

[1]Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001
[3]Department Of Pharmacology, Shri Venkateshwara School of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India
Corresponding author:
*Name & Address of Corresponding – Mithul V Mammen**
E-mail ID:mithulvmammne@gmail.com
Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001

ABSTRACT
Neuropathic pain, a chronic condition resulting from lesions or diseases of the somatosensory nervous system, significantly impacts quality of life due to symptoms like burning, shooting pain, allodynia, and hyperalgesia . This review synthesizes current knowledge on its epidemiology, pathophysiology, causes, comorbidities, diagnosis, treatment, and future research directions. Affecting 7-10% of the general population, neuropathic pain is prevalent in conditions such as diabetes (20-30%), chemotherapy-induced peripheral neuropathy (up to 90%), and congestive heart failure (CHF). Pathophysiological mechanisms involve ectopic nerve firing, central sensitization, and neuroinflammation driven by microglia and cytokines. Key triggers include diabetes, infections, and chemotherapy, with CHF-linked ischemia as an emerging factor. Diagnosis utilizes tools like the DN4 questionnaire, while treatments include SNRIs, gabapentinoids, and emerging therapies like suzetrigine. Despite advances, refractory cases highlight the need for novel targets, such as Orai1 channels, and personalized medicine approaches. This review emphasizes evidence-based strategies and integrative care to address the global burden of neuropathic pain.

Keywords Neuropathic pain, somatosensory system, allodynia, hyperalgesia, central sensitization, neuroinflammation, chemotherapy-induced peripheral neuropathy (CIPN)

1. INTRODUCTION

Neuropathic pain is a chronic pain syndrome arising from lesions or diseases affecting the somatosensory nervous system, distinct from nociceptive pain, which stems from tissue damage. The International Association for the Study of Pain (IASP) defines it as "pain caused by a lesion or disease of the somatosensory nervous system," emphasizing its neurological origin [1]. This condition manifests as burning, shooting, or electric-shock-like sensations, often accompanied by allodynia and hyperalgesia, severely impacting quality of life, sleep, and mental health [2].

1.1 Historical Context and Global Burden

Historically, neuropathic pain was underrecognized, but advancements in neurophysiology and imaging have illuminated its complexity. Early descriptions in the 19th century linked it to nerve injuries, but modern research reveals intricate interactions between neurons, glia, and immune cells [3]. The global burden is substantial, with millions affected, leading to high healthcare costs and lost productivity. In

developed countries, it contributes to opioid misuse and depression, underscoring the need for better management strategies [4].

1.2 Epidemiological Overview

Epidemiologically, neuropathic pain affects diverse populations, with higher rates in diabetics, cancer survivors, and the elderly. Its pathophysiology involves ectopic firing in damaged nerves, central sensitization, and disinhibition of pain pathways [5]. Peripheral mechanisms include sodium channel upregulation, while central processes feature synaptic plasticity in the spinal cord and brain [6]. Neuroinflammation, driven by microglia and cytokines, perpetuates the cycle [7].

1.3 Scope of the Review

This review integrates four key figures depicting mechanistic pathways and one on congestive heart failure (CHF) pathogenesis to explore overlaps. Figure 1 illustrates reactive oxygen species (ROS) generation in mitochondria and microglia, leading to cytokine release and neuronal damage [8]. Figure 2 outlines a cascade from nerve damage to sensitization via diamine oxidase (DAO), ATP depletion, and MAPK signaling [9]. Figures 3 and 4 focus on neurotoxic triggers in chemotherapy-induced peripheral neuropathy (CIPN), highlighting microglial reactivity and structural changes in nerves. Figure 5 depicts CHF pathways, potentially linking to neuropathic manifestations through ischemia [10].



Figure 1 Caption: Schematic representation of the mechanistic cascade from nerve damage to pain, highlighting the roles of DAO dysfunction, NMDA receptor activation, ROS generation, PKC activation, MAPK signaling, cytokine release, and central/peripheral sensitization [9].



Figure 2 : The diagram illustrates the role of oxidative stress in neuroinflammation, depicting how mitochondrial dysfunction in neurons leads to TCA cycle disruption, ATP/ADP imbalance, and ROS production via NADPH oxidase (NOX2). These ROS activate protein kinase C epsilon (PKCε), promoting the release of pro-inflammatory cytokines TNF-α and IL-1β from microglia, exacerbating neuronal damage.

Understanding these elements is crucial for developing targeted therapies. Despite available treatments, many patients remain refractory, necessitating a review of current knowledge and future prospects [11]. This paper aims to provide a thorough synthesis, emphasizing evidence-based insights for clinicians and researchers.

2. EPIDEMIOLOGY

The prevalence of neuropathic pain varies by population and methodology, but systematic reviews estimate it at 7-10% in the general population. A UK Biobank study reported 9.2% prevalence, associating it with lower quality of life and socioeconomic factors [12]. In the US, probable neuropathic pain affects about 10%, with higher rates in certain demographics like Hispanics [13].

Risk factors include diabetes (20-30% prevalence), herpes zoster, and surgery [14]. In cancer patients, CIPN can reach 90% [15]. Age, sex, and genetics influence susceptibility; women may experience more severe symptoms due to hormonal differences [16]. Comorbidities amplify prevalence in CHF; pain is common but understudied, potentially due to neuropathy from ischemia or medications [17]. Global disparities exist, with higher rates in developing countries from infections and trauma [18].



Figure 3: The chart displays the prevalence of a condition across different populations, with the highest prevalence (approximately 85%) observed in cancer patients (CIPN). Other groups, including the general population in the UK (around 10%), the general population in the US (around 15%), and diabetic patients (around 30%), show significantly lower prevalence rates.

Table 1: Epidemiological Data on Neuropathic Pain

Population	Prevalence (%)	Key Risk Factors	References
General Population (UK)	9.2	Socioeconomic status	[12]
General Population (US)	10	Hispanic ethnicity	[13]
Diabetic Patients	20-30	Hyperglycemia	[14]
Cancer Patients (CIPN)	90	Chemotherapy exposure	[15]
CHF Patients	Variable	Ischemia, medications	[17]

3. Pathophysiology and Mechanisms

3.1 Pathophysiology of Neuropathic Pain

Neuropathic pain arises from a lesion or disease affecting the somatosensory nervous system, leading to chronic pain that is often debilitating and impacts quality of life. Unlike nociceptive pain, which serves a protective function, neuropathic pain is maladaptive and results from abnormal neural signaling without ongoing tissue damage. It can be triggered by various conditions, including diabetes (diabetic neuropathy), infections like herpes zoster (postherpetic neuralgia), nerve trauma, compression (e.g., carpal tunnel syndrome), chemotherapy-induced peripheral neuropathy, or central nervous system disorders such as multiple sclerosis or stroke [19]. The pathophysiology involves structural and functional alterations in both peripheral and central components of the nervous system, resulting in spontaneous

pain, hyperalgesia (increased sensitivity to painful stimuli), and allodynia (pain from non-painful stimuli like light touch).

The process typically begins with an initial insult to the nerves, such as axonal damage, demyelination, or inflammation, which disrupts normal signal transmission. This leads to ectopic (abnormal) impulse generation in damaged neurons, amplifying pain signals. Over time, neuroplastic changes occur, including neuronal sprouting, synaptic reorganization, and glial cell activation, perpetuating the pain state even after the initial injury resolves. In peripheral neuropathies, damage to small unmyelinated C-fibers and thinly myelinated A-delta fibers is common, while central neuropathies involve spinal cord or brain lesions. Genetic factors, such as mutations in voltage-gated sodium channels (e.g., Nav1.7), can also predispose individuals to heightened pain susceptibility [20].

3.2 Mechanisms of Neuropathic Pain

The mechanisms underlying neuropathic pain are multifaceted, involving peripheral sensitization, central sensitization, and neuroimmune interactions. These can be broadly categorized as follows:

3.2.1 Peripheral Mechanisms

- **Ectopic Activity and Ion Channel Dysregulation**: Damaged peripheral nerves develop abnormal excitability, generating spontaneous electrical impulses (ectopic firing) at sites like neuromas (nerve endings) or demyelinated segments. This is often due to upregulation or redistribution of voltage-gated sodium channels (e.g., Nav1.3, Nav1.7, Nav1.8), which lower the threshold for action potential initiation. Transient receptor potential (TRP) channels, such as TRPV1 (activated by heat and capsaicin) and TRPM8 (cold-sensitive), also contribute to hypersensitivity [21].
- **Peripheral Sensitization**: Injured nociceptors become hypersensitive due to inflammatory mediators released from damaged tissues or immune cells. These include prostaglandins, bradykinin, and cytokines (e.g., TNF-α, IL-1β), which phosphorylate ion channels and receptors, enhancing neuronal excitability. In chemotherapy-induced neuropathy, drugs like platinum compounds or taxanes directly damage axons, leading to mitochondrial dysfunction and oxidative stress [22].
- **Sympathetic Nervous System Involvement**: In some cases, like complex regional pain syndrome, sympathetic fibers sprout around dorsal root ganglia, coupling pain with autonomic responses (e.g., sweating, vasomotor changes) [23].

3.2.2 Central Mechanisms

- **Central Sensitization**: At the spinal cord level, persistent peripheral input leads to amplified synaptic transmission in the dorsal horn. This involves NMDA receptor activation, which removes the magnesium block and allows calcium influx, triggering intracellular cascades that enhance neuronal responsiveness (wind-up phenomenon). Protein kinase C and other kinases phosphorylate receptors, increasing glutamate release and reducing the pain threshold [24].
- **Loss of Inhibitory Control**: Descending inhibitory pathways from the brainstem (e.g., involving serotonin and norepinephrine) become dysfunctional, while local GABAergic and glycinergic inhibition in the spinal cord diminishes. This disinhibition allows non-painful inputs (e.g., from A-beta touch fibers) to activate pain pathways, causing allodynia [25].
- **Neuroplasticity and Reorganization**: Chronic pain induces structural changes, such as cortical remapping in the somatosensory cortex or thalamic bursting activity. Glial cells (microglia and astrocytes) activate, releasing pro-inflammatory cytokines that sustain central sensitization [26].



Figure 2 : Illustrating the progression from a neurotoxic trigger to neuropathic pain. It shows a damaged neuron with a neurotoxic trigger leading to reactive microgliosis and activated microglia, which secrete factors causing neuronal damage. This results in nerve damage, releasing chemical signals like cytokines that lead to inflammation, sensitization of neurons, and the development of neuropathic pain. The diagram highlights the neuron's structure (dendrites, soma, axon, myelin sheath) and the involvement of various compounds (e.g., Dorsal Root Ganglion, Platinum compounds, Taxanes, Bortezomib) and cellular components (e.g., mitochondria, Schwann cells) in the process. It also depicts the role of increased expression of pain-related factors and the involvement of small nerve fibers and axon terminals in neuropathic pain development.

3.2.3 Neuroimmune and Inflammatory Mechanisms

Immune cells infiltrate damaged nerves, releasing chemokines and cytokines that activate microglia in the spinal cord, forming a feedback loop of inflammation and pain amplification. This is particularly evident in conditions like HIV neuropathy or post-injury states [27].

Table 2: Key Mechanisms in Neuropathic Pain

Mechanism	Key Players	Pathway Impact	References
Peripheral Sensitization	Nav1.7, Nav1.8	Ectopic firing	[21]
Central Sensitization	NMDA, AMPA receptors	LTP, wind-up	[24]
ROS Generation	NADPH oxidase, PKCε	Oxidative stress	[8]
Microglial Activation	TNF-α, IL-1β	Neuroinflammation	[7]
CIPN-Specific	Paclitaxel, microtubules	Axonal degeneration	[22]

4. CAUSES AND TRIGGERS

Neuropathic pain arises from various triggers, including trauma, infections, metabolic disorders, and toxins. Diabetes causes hyperglycemia-induced oxidative stress, damaging nerves [5]. Postherpetic neuralgia follows herpes zoster reactivation [28]. CIPN is prominent, affecting sensory nerves with drugs like taxanes, platinum compounds, vincalkaloids, and bortezomib [29]. Mechanisms include axonal degeneration, calcium dysregulation, mitochondrial damage, and ROS [22]. Figure 3 details affected structures (dorsal root ganglion, axons, myelin) and downstream effects like increased nociceptor excitability [30]. Pattern recognition receptors mediate this in CIPN [31]. Central changes, like brain plasticity, amplify symptoms [32]. Other causes include autoimmune diseases, channelopathies, and spinal injuries [16]. Prevention in CIPN includes dose adjustment and neuroprotective agents [33].

Table 3: Common Causes and Triggers of Neuropathic Pain

Cause/Trigger	Mechanism	Affected Structures	References
Diabetes	Oxidative stress	Peripheral nerves	[5]
Herpes Zoster	Viral reactivation	Dorsal root ganglia	[28]
Chemotherapy (CIPN)	Microtubule disruption	Axons, myelin	[29]
Autoimmune Diseases	Immune-mediated damage	Nerves, CNS	[16]
Spinal Injury	Trauma-induced lesion	Spinal cord	[16]

5. COMORBIDITIES: FOCUS ON CONGESTIVE HEART FAILURE

Neuropathic pain often coexists with systemic diseases, complicating management. In CHF, pain prevalence is high, associated with reduced quality of life [17]. Mechanisms include ischemia-induced neuropathy and sympathetic overactivity [10]. Figure 5 shows CHF pathogenesis: hypertension and coronary disease lead to vasoconstriction, plaque, obstruction, reduced output, and congestion [34]. This may cause nerve ischemia, mimicking neuropathic pain [35]. Comorbid depression and anxiety worsen outcomes [36]. Medications like gabapentinoids can exacerbate CHF [37]. Management requires integrated care [38].

Table 4: Comorbidities and Neuropathic Pain in CHF

Comorbidity	Mechanism Link	Clinical Impact	References
CHF	Ischemia, inflammation	Increased pain severity	[17]
Depression	Neurotransmitter imbalance	Worsened quality of life	[36]
Anxiety	Sympathetic overdrive	Amplified symptoms	[36]
Medication Effects	Gabapentinoid side effects	Cardiac decompensation	[37]

6. DIAGNOSIS

Diagnosis relies on history, examination, and tools like DN4 (sensitivity 83%) [39]. Neurophysiological tests unveil mechanisms [6]. Imaging and biopsies confirm lesions [40].

Table 5: Diagnostic Tools for Neuropathic Pain

Tool/Method	Purpose	Sensitivity/Specificity	References
DN4 Questionnaire	Screening	83% / 90%	[39]
PainDETECT	Symptom assessment	85% / 80%	[39]
Nerve Conduction	Functional assessment	Variable	[6]
MRI Imaging	Structural lesion detection	High specificity	[40]
Biopsy	Histopathological confirmation	High accuracy	[40]

7. TREATMENT AND MANAGEMENT

First-line treatments include SNRIs (duloxetine), gabapentinoids, and TCAs [41]. Guidelines recommend multimodal approaches [11]. Emerging therapies include suzetrigine for diabetic peripheral neuropathy [42]. Non-pharmacological options include spinal cord stimulation and cognitive therapy [43]. For CIPN, duloxetine is effective [44].

Table 6: Treatment Options for Neuropathic Pain

Category	Treatment	Mechanism/Action	References
Pharmacological	Duloxetine (SNRI)	Serotonin/norepinephrine reuptake inhibition	[41]
Pharmacological	Gabapentin	Calcium channel modulation	[41]
Pharmacological	Amitriptyline (TCA)	Sodium channel blockade	[41]
Emerging	Suzetrigine	Nav1.8 inhibition	[42]
Non-Pharmacological	Spinal Cord Stimulation	Pain signal modulation	[43]
Non-Pharmacological	Cognitive Therapy	Psychological coping	[43]

8. FUTURE DIRECTIONS

Research focuses on biomarkers and novel targets like Orai1 channels [45]. Personalized medicine via pharmacogenomics [46] and advanced models and trials promise breakthroughs [47].

Table 7: Future Research Directions

Area	Focus	Potential Impact	References
Biomarkers	Pain-specific markers	Early diagnosis	[45]
Novel Targets	Orai1 channels	Targeted therapy	[45]
Pharmacogenomics	Genetic profiling	Personalized treatment	[46]
Clinical Trials	New drug testing	Improved efficacy	[47]

9. CONCLUSION

Neuropathic pain's complexity demands integrated approaches. Advances in mechanisms and treatments offer hope, but gaps remain [48].

REFERENCES

1. International Association for the Study of Pain. Epidemiology of Neuropathic Pain: How Common is Neuropathic Pain, and What Is Its Impact? 2014.
2. Rugnath R, Orzechowicz C, Newell C, Carullo V, Rugnath A. A Literature Review: The Mechanisms and Treatment of Neuropathic Pain—A Brief Discussion. Biomedicines. 2024;12(1):204. doi:10.3390/biomedicines12010204. PMID:38255308.
3. Pessôa BL, Hauwanga WN, Thomas A, Valentim G, McBenedict B. A Comprehensive Narrative Review of Neuropathic Pain: From Pathophysiology to Surgical Treatment. Cureus. 2024;16(4):e58025. doi:10.7759/cureus.58025. PMID:38738050.
4. Baron R, Dickenson AH. Neuropathic pain; what we know and what we should do about it. Front Pain Res. 2023;4:1220034. doi:10.3389/fpain.2023.1220034.
5. Demartini L, Bonezzi C. Neuropathic pain: proposal of a mechanism-based treatment. Explor Neurosci. 2025;4:100686. doi:10.37349/en.2025.100686.
6. Leone CM, Truini A. Understanding neuropathic pain: the role of neurophysiological tests in unveiling underlying mechanisms. J Anesth Analg Crit Care. 2024;4:66. doi:10.1186/s44158-024-00212-z.
7. Karavis MY, Siafaka I, Vadalouca A, Georgoudis G. Role of Microglia in Neuropathic Pain. Cureus. 2023;15(8):e43555. doi:10.7759/cureus.43555. PMID:37719474.
8. Kallenborn-Gerhardt W, Schröder K, Del Turco D, Lu R, Kynast K, Kosowski J, et al. Nox2-dependent signaling between macrophages and sensory neurons contributes to neuropathic pain hypersensitivity. Pain. 2014;155(10):2161-70. doi:10.1016/j.pain.2014.08.013.
9. Li X, Wang Y, Zhang L, et al. Research progress on the mechanism of chronic neuropathic pain. IBRO Neurosci Rep. 2023;14:80-85. doi:10.1016/j.ibneur.2022.12.007.
10. Alemzadeh-Ansari MJ, Ansari-Ramandi MM, Naderi N. Chronic Pain in Chronic Heart Failure: A Review Article. J Teh Univ Heart Ctr. 2017;12(2):49-56. doi:10.18502/jthc.v12i2.468. PMID:28828019.
11. Moisset X. Neuropathic pain: Evidence based recommendations. Presse Med. 2024;53(2):104232. doi:10.1016/j.lpm.2024.104232. PMID:38641202.
12. Baskozos G, Hébert HL, Pascal MMV, Themistocleous AC, Macfarlane GJ, Wynick D, Bennett DLH, Smith BH. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors

in UK Biobank. Pain Reports. 2023;8(2):e1066. doi:10.1097/PR9.0000000000001066. PMID:37090682.
13. DiBonaventura MD, Sadosky A, Concialdi K, Hopps M, Kudel I, Parsons B, Cappelleri JC, Hlavacek P, Alexander AH, Stacey BR, Markman JD, Farrar JT. The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey. J Pain Res. 2017;10:2525-2538. doi:10.2147/JPR.S127014.
14. Baskozos G, Hébert HL, Pascal MMV, Themistocleous AC, Macfarlane GJ, Wynick D, Bennett DLH, Smith BH. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. PAIN Reports. 2023;8(2):e1066. doi:10.1097/PR9.0000000000001066.
15. Stubblefield MD. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021;48(3):193-207. doi:10.1053/j.seminoncol.2021.09.004.
16. Kaye AD, Armistead G, Amedio LS, Manthei ME, Ahmadzadeh S, Bernhardt B, Shekoohi S. Evolving treatment strategies for neuropathic pain: a narrative review. Medicina. 2025;61(6):1063. doi:10.3390/medicina61061063.
17. Goodlin SJ, Wingate S, Pressler SJ, Teerlink JR, Storey CP, Nelson JE, et al. Investigating pain in heart failure patients: rationale and design of the Pain Assessment, Incidence & Nature in Heart Failure (PAIN-HF) study. J Card Fail. 2008;14(3):211-6. doi:10.1016/j.cardfail.2008.01.008.
18. van Velzen M, Dahan A, Niesters M. Neuropathic Pain: Challenges and Opportunities. Front Pain Res. 2020;1:1. doi:10.3389/fpain.2020.00001.
19. Petroianu GA, Aloum L, Adem A. Neuropathic pain: Mechanisms and therapeutic strategies. Front Cell Dev Biol. 2023;11:1072629. doi:10.3389/fcell.2023.1072629.
20. Chen X, Gan Y, Au NPB, Ma CHE. Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2024;17:1345811. doi:10.3389/fnmol.2024.1345811.
21. Flatters SJL, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122(3):245-257. doi:10.1016/j.pain.2006.01.024. PMID:16530964.
22. Staff NP, Fehrenbacher JC. Chemotherapy-Induced Peripheral Neuropathy: Mechanisms and Therapeutic Avenues. Neurotherapeutics. 2021;18(4):2384-2396. doi:10.1007/s13311-021-01142-2.
23. Boyette-Davis JA, Hou S, Abdi S, Dougherty PM. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018;8(5):363–375. doi:10.2217/pmt-2018-0020. PMID:30212277.
24. Avallone A, Bimonte S, Cardone C, Cascella M, Cuomo A. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res. 2022;42(10):4667-4688. doi:10.21873/anticanres.15967. PMID:36191987.
25. Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2:16. doi:10.1186/s42466-020-00063-3. PMID:33324922.
26. Barcelon EE, Cho W-H, Jun SB, Lee SJ. Brain microglial activation in chronic pain-associated affective disorder. Front Neurosci. 2019;13:213. doi:10.3389/fnins.2019.00213. PMID:30949019.
27. Long J, Tian G, et al. The role of microglia in neuropathic pain: A systematic review of animal experiments. Brain Res Bull. 2025;111410. doi:10.1016/j.brainresbull.2025.111410.
28. Reynolds CA, Minic Z. Chronic Pain-Associated Cardiovascular Disease: The Role of Sympathetic Nerve Activity. Int J Mol Sci. 2023;24(6):5378. doi:10.3390/ijms24065378. PMID:36982464.
29. Chin X, Gao Y, Au NPB, Ma CHE. Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2024;17. doi:10.3389/fnmol.2024.1345811.
30. Shastry S, Mizrahi D, Kanzawa-Lee G. The Future of Chemotherapy: The Mechanisms and Benefits of Exercise in Taxane-Induced Peripheral Neuropathy. Physiologia. 2023;3(4):563-584. doi:10.3390/physiologia3040042.

31. Greeshma N, Prasanth VV, Balaji B, Karthikeyan R, Jaber M, Chishti MA, George M, Elossaily GM, Kapadia M, Sahreen S. Role of pattern recognition receptors in chemotherapy-induced neuropathic pain. Brain. 2024;147(3):1025-1042. doi:10.1093/brain/awad294. PMID:37665947.
32. Cunha M, Tavares I, Costa-Pereira JT. Centralizing the Knowledge and Interpretation of Pain in Chemotherapy-Induced Peripheral Neuropathy: A Paradigm Shift towards Brain-Centric Approaches. Brain Sci. 2024;14(7):659. doi:10.3390/brainsci14070659.
33. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399.
34. Yowtak J, Lee KY, Kim HY, Wang J, Kim HK, Chung K, Chung JM. Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain. 2011;152(4):844-852. doi:10.1016/j.pain.2010.12.034. PMID:21296500.
35. Bhangale JO, Acharya SR. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-l-cysteine in rats. Eur J Pain. 2006;10(7):573-9. doi:10.1016/j.ejpain.2005.08.006.
36. Mhesin D, Nazzal H, Amerah J, Abu-Ali H, Issa Y, Dabbas Y, et al. Prevalence of pain and its association with quality of life of patients with heart failure in a developing country: findings from a multicenter cross-sectional study. BMC Cardiovasc Disord. 2022;22:426. doi:10.1186/s12872-022-02864-7.
37. Smith AB, Pressler SJ. Chronic Pain in Heart Failure: An Urgent Need for Improved Characterization and Treatment. Journal of Cardiovascular Nursing. 2025;40(1):6. doi:10.1097/JCN.0000000000001115.
38. Dash SS, Khatri NK, Divyateja S, Bhate J, Rao GKS. Advances in neuropathic pain management: A review of real-world studies. J Curr Res Sci Med. 2024;10(1):15-24. doi:10.4103/jcrsm.jcrsm_132_23.
39. Ahmadi R, Kuner R, Weidner N, Keßler J, Bendszus M, Krieg SM. The diagnosis and treatment of neuropathic pain. Dtsch Arztebl Int. 2024;121(25):825-32. doi:10.3238/arztebl.m2024.0215.
40. Carrasco C, Naziroğlu M, Rodríguez AB, Pariente JA. Neuropathic Pain: Delving into the Oxidative Origin and the Possible Implication of Transient Receptor Potential Channels. Front Physiol. 2018;9:95. doi:10.3389/fphys.2018.00095. PMID:29483854.
41. Sadegh AA, Gehr NL, Finnerup NB. A systematic review and meta-analysis of randomized controlled head-to-head trials of recommended drugs for neuropathic pain. PAIN Reports. 2024;9(2):e1138. doi:10.1097/PR9.0000000000001138.
42. Vertex Pharmaceuticals. Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain. 2024.
43. Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023;131(1):79-92. doi:10.1016/j.bja.2023.04.021. PMID:37210279.
44. US Pharm. 2015;40(1):HS5-HS10.
45. Toth AB, Jairaman A, Kountz TS, et al. Regulation of neuropathic pain by microglial Orai1 channels. Sci Adv. 2023;9(14):eade7002. doi:10.1126/sciadv.ade7002.
46. Sadegh AA, Gehr NL, Finnerup NB. Personalized outcomes in neuropathic pain: a clinical relevance and assay sensitivity analysis of randomized controlled trials. Pain. 2025;166(1):31-42. doi:10.1097/j.pain.0000000000003306. PMID:39365731.
47. Wu Y, et al. Neuropathic Pain: A Comprehensive Bibliometric Analysis of Emerging Trends and Future Research Directions. J Pain Res. 2025;18:1117-1132. doi:10.2147/JPR.S458818. PMID:38572190.
48. Torrance N, Smith BH, Bennett MI, Lee AJ. Neuropathic pain in the general population: A systematic review of epidemiological studies. Pain. 2014;155(4):654-662. doi:10.1016/j.pain.2013.11.013.